Watchlist Price Alert

AstraZeneca (AZN)

NASDAQ: AZN · Real-Time Price · USD

73.63

-0.79 (-1.06%)

At close: Jun 16, 2025, 2:16 PM

-1.06% (1D)

Bid	73.62
Market Cap	456.56B
Revenue (ttm)	54.98B
Net Income (ttm)	7.77B
EPS (ttm)	2.49
PE Ratio (ttm)	29.57
Forward PE	14.73
Analyst	Buy

Ask	73.64
Volume	2,359,758
Avg. Volume (20D)	5,366,366
Open	74.38
Previous Close	74.42
Day's Range	73.52 - 74.75
52-Week Range	61.24 - 87.68
Beta	0.17

About AZN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AZN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AZN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

+2.77%

AstraZeneca shares are trading higher after the co... Unlock content with Pro Subscription

1 month ago

-2.2%

Shares of pharmaceutical stocks are trading lower. The sector may down on continued weakness amid President Trump's drug pricing executive order.

News

Just now · proactiveinvestors.co.uk

Is Trump targeting the NHS in trade negotiations? This reports says it is

Britain could face higher drug costs as part of a deal to stave off future tariffs from Donald Trump, according to a report in the Daily Telegraph. Documents released after a recent trade agreement sh...

2 days ago · seekingalpha.com

5 Ideal 'Safer' Dividend Buys From Bloomberg's June Watch List

I highlight 15 dividend-paying stocks from Bloomberg's 50 Companies to Watch that meet my 'safer' criteria: free cash flow yields exceed dividend yields. The top ten dividend focus stocks offer an est...

3 days ago · proactiveinvestors.co.uk

AstraZeneca bets big on AI and China with $3.6bn CSPC collaboration

AstraZeneca PLC (LSE:AZN) is betting big on AI-enabled drug discovery (and China), agreeing a research collaboration with China's CSPC Pharmaceutical Group that could see the Anglo-Swedish drugmaker p...

3 days ago · wsj.com

AstraZeneca Teams Up With CSPC Pharmaceuticals With Deal Valued at Up to $5.33 Billion

The deal with China's CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of new drug candidates.

3 days ago · reuters.com

AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC

AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 billion to focus on AI-enabled initiatives.

3 days ago · proactiveinvestors.co.uk

Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes

UBS has reiterated its 'buy' rating on AstraZeneca PLC (LSE:AZN) with a 12-month price target of 14,200p, offering potential upside of just over 30% from the current share price of 10,907p. The focus ...

1 week ago · zacks.com

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

1 week ago · youtube.com

AstraZeneca CEO: We totally agree with President Trump on this

AstraZeneca CEO Pascal Soriot unpacks President Donald Trump's drug cost cut executive order on 'The Claman Countdown.' #foxbusiness #health #trump #maha